Biotech acquisition
-
Johnson & Johnson’s $3 Billion Bet: Halda Therapeutics Acquisition Ushers in Next-Gen Cancer Drug Era
Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05 billion signals a pivotal moment in cancer treatment innovation, spotlighting the promise of RIPTAC™ and targeted protein degradation technologies.
-
Novartis’s $12 Billion Acquisition of Avidity Biosciences Reshapes RNA Therapeutics Landscape
Novartis AG is set to acquire Avidity Biosciences for $12 billion, marking a pivotal moment in RNA therapeutics, with Avidity’s precision cardiology programs spinning off into a new company and Novartis gaining access to groundbreaking neuromuscular drug candidates.